Cargando…

CDK4/CDK6 Inhibitors Synergize with Midostaurin, Avapritinib, and Nintedanib in Inducing Growth Inhibition in KIT D816V(+) Neoplastic Mast Cells

SIMPLE SUMMARY: Advanced systemic mastocytosis (AdvSM) is a rare malignant disease with a poor prognosis due to the drug resistance of neoplastic mast cells. We found that drugs targeting the cell cycle regulators CDK4 and CDK6 profoundly suppress the growth and survival of neoplastic mast cells. Fu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Schneeweiss-Gleixner, Mathias, Filik, Yüksel, Stefanzl, Gabriele, Berger, Daniela, Sadovnik, Irina, Bauer, Karin, Smiljkovic, Dubravka, Eisenwort, Gregor, Witzeneder, Nadine, Greiner, Georg, Hoermann, Gregor, Schiefer, Ana-Iris, Schwaab, Juliana, Jawhar, Mohamad, Reiter, Andreas, Sperr, Wolfgang R., Arock, Michel, Valent, Peter, Gleixner, Karoline V.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9264943/ https://www.ncbi.nlm.nih.gov/pubmed/35804842 http://dx.doi.org/10.3390/cancers14133070

Ejemplares similares

CDK4/CDK6 inhibition as a novel strategy to suppress the growth and survival of BCR-ABL1(T315I)+ clones in TKI-resistant CML
por: Schneeweiss-Gleixner, Mathias, et al.
Publicado: (2019)

Inhibitory effects of midostaurin and avapritinib on myeloid progenitors derived from patients with KIT D816V positive advanced systemic mastocytosis
por: Lübke, Johannes, et al.
Publicado: (2019)

The KIT and PDGFRA switch-control inhibitor DCC-2618 blocks growth and survival of multiple neoplastic cell types in advanced mastocytosis
por: Schneeweiss, Mathias, et al.
Publicado: (2018)

Identification of a Leukemia-Initiating Stem Cell in Human Mast Cell Leukemia
por: Eisenwort, Gregor, et al.
Publicado: (2019)

Cell‐based and antibody‐mediated immunotherapies directed against leukemic stem cells in acute myeloid leukemia: Perspectives and open issues
por: Valent, Peter, et al.
Publicado: (2020)

P1014: OVERALL SURVIVAL IN PATIENTS WITH ADVANCED SYSTEMIC MASTOCYTOSIS RECEIVING AVAPRITINIB VERSUS MIDOSTAURIN OR CLADRIBINE
por: Reiter, A., et al.
Publicado: (2022)

Identification of CD203c as a New Basophil-Specific Flow-Marker in Ph(+) Chronic Myeloid Leukemia
por: Sadovnik, Irina, et al.
Publicado: (2022)

FLAG-induced remission in a patient with acute mast cell leukemia (MCL) exhibiting t(7;10)(q22;q26) and KIT D816H()
por: Valent, Peter, et al.
Publicado: (2013)

Immunotherapy-Based Targeting and Elimination of Leukemic Stem Cells in AML and CML
por: Valent, Peter, et al.
Publicado: (2019)

Engraftment in NSG(SCF) mice correlates with the WHO category and prognosis in systemic mastocytosis
por: Willmann, Michael, et al.
Publicado: (2023)

Drug-induced inhibition of phosphorylation of STAT5 overrides drug resistance in neoplastic mast cells
por: Peter, Barbara, et al.
Publicado: (2017)

Phenotypic Characterization of Leukemia-Initiating Stem Cells in Chronic Myelomonocytic Leukemia
por: Eisenwort, Gregor, et al.
Publicado: (2021)

Avapritinib treatment of KIT D816V-mutant atypical chronic myeloid leukemia
por: Sandow, Lyndsey, et al.
Publicado: (2023)

BRD4 degradation blocks expression of MYC and multiple forms of stem cell resistance in Ph(+) chronic myeloid leukemia
por: Peter, Barbara, et al.
Publicado: (2022)

Identification of bromodomain-containing protein 4 (BRD4) as a novel marker and epigenetic target in mast cell leukemia
por: Wedeh, Ghaith, et al.
Publicado: (2015)

Secondary basophilic leukemia in Ph-negative myeloid neoplasms: A distinct subset with poor prognosis
por: Berger, Daniela, et al.
Publicado: (2021)

Proposed Diagnostic Criteria and Classification of Canine Mast Cell Neoplasms: A Consensus Proposal
por: Willmann, Michael, et al.
Publicado: (2021)

Molecular quantification of tissue disease burden is a new biomarker and independent predictor of survival in mastocytosis
por: Greiner, Georg, et al.
Publicado: (2020)

Multidisciplinary Challenges in Mastocytosis and How to Address with Personalized Medicine Approaches
por: Valent, Peter, et al.
Publicado: (2019)

N‐terminal pro‐brain natriuretic peptide is a prognostic marker for response to intensive chemotherapy, early death, and overall survival in acute myeloid leukemia
por: Graf, Irene, et al.
Publicado: (2023)

Phenotyping and Target Expression Profiling of CD34(+)/CD38(−) and CD34(+)/CD38(+) Stem- and Progenitor cells in Acute Lymphoblastic Leukemia
por: Blatt, Katharina, et al.
Publicado: (2018)

Preclinical human models and emerging therapeutics for advanced systemic mastocytosis
por: Arock, Michel, et al.
Publicado: (2018)

The pan-BCL-2-blocker obatoclax (GX15-070) and the PI3-kinase/mTOR-inhibitor BEZ235 produce cooperative growth-inhibitory effects in ALL cells
por: Stefanzl, Gabriele, et al.
Publicado: (2017)

Efficacy of avapritinib versus best available therapy in the treatment of advanced systemic mastocytosis
por: Reiter, Andreas, et al.
Publicado: (2022)

Avapritinib for Cutaneous Mastocytosis
por: LEE, Hannah, et al.
Publicado: (2021)

Small Molecule Tyrosine Kinase Inhibitor Nintedanib Reduces Development of Cardiac Allograft Vasculopathy in Murine Aortic Allografts
por: Gocht, Annika, et al.
Publicado: (2018)

The interplay of CDK4 and CDK6 in melanoma
por: Kollmann, Karoline, et al.
Publicado: (2019)

Ludwig Boltzmann Cluster Oncology (LBC ONC): first 10 years and future perspectives
por: Valent, Peter, et al.
Publicado: (2018)

Genetic Regulation of Tryptase Production and Clinical Impact: Hereditary Alpha Tryptasemia, Mastocytosis and Beyond
por: Sprinzl, Bettina, et al.
Publicado: (2021)

TKI rotation-induced persistent deep molecular response in multi-resistant blast crisis of Ph+ CML
por: Valent, Peter, et al.
Publicado: (2017)

Cyclin K goes with Cdk12 and Cdk13
por: Kohoutek, Jiri, et al.
Publicado: (2012)

Long-term treatment with imatinib results in profound mast cell deficiency in Ph+ chronic myeloid leukemia
por: Cerny-Reiterer, Sabine, et al.
Publicado: (2014)

CDK3, CDK5 and CDK8 Proteins as Prognostic and Potential Biomarkers in Colorectal Cancer Patients
por: Wang, Dan, et al.
Publicado: (2022)

Efficacy and safety of avapritinib in previously treated patients with advanced systemic mastocytosis
por: Reiter, Andreas, et al.
Publicado: (2022)

The CDK-activating kinase Cdk7: Taking yes for an answer
por: Schachter, Miriam Merzel, et al.
Publicado: (2013)

Regulatory functions of the Mediator kinases CDK8 and CDK19
por: Fant, Charli B., et al.
Publicado: (2018)

Multiple CDK inhibitor dinaciclib suppresses neuroblastoma growth via inhibiting CDK2 and CDK9 activity
por: Chen, Zhenghu, et al.
Publicado: (2016)

Inducible deletion of CDK4 and CDK6 – deciphering CDK4/6 inhibitor effects in the hematopoietic system
por: Maurer, Barbara, et al.
Publicado: (2020)

Clinical Impact of Inherited and Acquired Genetic Variants in Mastocytosis
por: Nedoszytko, Boguslaw, et al.
Publicado: (2021)

The Role of Avapritinib for the Treatment of Systemic Mastocytosis
por: Sumbly, Vikram, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_rje33ahm1spct6qbf29schgrv9